|
EORTC AISBL / IVZW |
|
|
EORTC AISBL / IVZW |
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 13001 | Phase I clinical trial of recombinant viscumin ( rViscumin,rMistletoe lectin,rML) administered twice weekly by the subcutaneous route in patients with solid tumors after failure of standard therapy |
| 16002 | Phase I clinical trial of recombinant mistletoe lectin (rML,rViscumin) administered twice weekly by the intravenous route in patients with solid tumors after failure of standard chemotherapy |
| 13992 | A phase I, open label multiple dose, safety and pharmacokinetic study of intravenously administered humanized anti-VEGF monoclonal antibody (HuMV833) to patients with relapsed or refractory solid tumors. |
| 06971 | A Phase III Study of PSC-833 in Combination with Vincristine, Doxorubicin and Dexamethasone (PSC-833/VAD) versus VAD Alone in Patients with Relapsing and Refractory Multiple Myeloma |
| 06964 | Phase II study of the efficacy of rH Inteleukin-2 in patients with slowly progressing acute myelogenous leukemia (AML) and with limited bone marrow blastosis after autologous stem cell transplantation or chemotherapy. |
| 08962 | A phase III study of Marimastat in patients with small cell lung cancer following a response to first line chemotherapy. |
| 06952 | Induction with All-Trans Retinoic Acid in combination with Idarubicin followed by intensive consolidation followed by bone marrow transplantation or a randomized maintenance treatment depending upon the amount of minimal residual disease in collaboration with GIMEMA-AIEOP Cooperative Groups) |
| 24921 | Phase II study of Interferon alpha and 5-fluorouracil in locally advanced or recurrent or metastatic squamous cell carcinoma of the head and neck |
| 30924 | Randomized phase II / III study of high dose intensity M-VAC chemotherapy + G-CSF versus classic M-VAC in advanced urothelial tract tumors |
| 06923 | Randomized phase III study testing the effect of bone marrow transplantation or conventional chemotherapy with or without alpha Interferon for aggressive myeloma |
| 06911 | Pilot study for the evaluation of rhGM-CSF before induction chemotherapy in hairy cell leukemia |
| 06915 | A randomized phase III trial of all transRetinoic Acid followed by conventional chemotherapy versus conventional chemotherapy alone in acute promyelocytic leukemia. |
| 06913 | Pilot Study of VAD (vincristine, doxorubicin, dexamethasone) combined with cyclosporin in patients with progressive multiple myeloma. |
| 06903 | A randomized phase III multicenter trial comparing LD-ARA-C alone versus LD-ARA-C + GM-CSF versus LD-ARA-C + recombinant interleukin-3 for patients with myelodysplastic syndromes and a high risk of developing acute leukemia |
| 06902 | A pilot multicenter study of recombinant human interleukin-3 (IL-3) plus LD-ARA-C in patients with myelodysplastic syndromes and a risk of developing acute leukemia |
| 06892 | A randomized phase III study on the value of GM-CSF administration as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myelogenous leukemia |
| 08883 | Phase III trial on the evaluation of gamma Interferon for intensification/ maintenance of complete or near complete response in small cell lung cancer |
| 06885 | A randomized phase I - II dose-finding study of human GM-CSF in patients with MDS at relatively low risk of developing acute leukemia |
| 06886 | Randomized phase II study with GM-CSF and low-dose ARA-C in patients with "high risk" myelodysplastic syndromes |
| 06872 | Phase II study of the effect of tumor necrosis factor (TNF-alpha) in refractory or relapsed acute non-lymphoblastic leukemia |
| 62043 | Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma |
| 18961 | Adjuvant ganglioside GM2-KLH/QS-21 Vaccination Post-operative adjuvant ganglioside GM2-KLH/QS-21 vaccination treatment vs observation after resection of primary cutaneous melanoma (AJCC stage II, T3-T4N0M0), a 2-arm multicenter randomized phase III trial |
| 06975 | A phase II Multicenter study of Amifostine in patients with myelodysplastic dyndromes at relatively low risk of developing acute leukemia |
| 06891 | A randomized phase I/II multicenter study of recombinant human interleukin-3 (IL-3) in patients with myelodysplastic syndromes at relatively low risk of developing acute leukemia. |
| 06023 | Randomized phase II trial with infliximab (Remicade (R)) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia. |
| 40071 | Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized phase II trial. |
| 06031 | Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP. |
| 11001 | 10B-uptake in different tumours using the boron compounds BSH and BPA. |
| 08061 | Phase II study of sunitinib (SU11248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a "sensitive" relapse. |
| 40051 | Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer (BOS). |
| 58941 | Cyclosporine A after autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission. A phase I/II trial |
| 40052 | Adjuvant treatment of fully resected stage III colon cancer with folfox-4 versus folfox-4 plus cetuximab (PETACC-8) |